Stephen K. Brannan - Aug 9, 2022 Form 4 Insider Report for Karuna Therapeutics, Inc. (KRTX)

Role
Chief Medical Officer
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Stock symbol
KRTX
Transactions as of
Aug 9, 2022
Transactions value $
-$5,496,678
Form type
4
Date filed
8/11/2022, 05:19 PM
Previous filing
Jul 11, 2022
Next filing
Sep 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $41.5K +5.7K +38.02% $7.27* 20.7K Aug 9, 2022 Direct
transaction KRTX Common Stock Sale -$1.3M -5.7K -27.55% $228.10 15K Aug 9, 2022 Direct F1, F2
transaction KRTX Common Stock Options Exercise $51.1K +7.03K +46.89% $7.27* 22K Aug 9, 2022 Direct
transaction KRTX Common Stock Sale -$1.6M -7.03K -31.92% $228.13 15K Aug 9, 2022 Direct F1
transaction KRTX Common Stock Options Exercise $113K +12.3K +81.76% $9.20* 27.3K Aug 9, 2022 Direct
transaction KRTX Common Stock Sale -$2.8M -12.3K -44.98% $228.05 15K Aug 9, 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -5.7K -22.95% $0.00 19.1K Aug 9, 2022 Common Stock 5.7K $7.27 Direct F4
transaction KRTX Option (right to buy) Options Exercise $0 -7.03K -36.74% $0.00 12.1K Aug 9, 2022 Common Stock 7.03K $7.27 Direct F4
transaction KRTX Option (right to buy) Options Exercise $0 -12.3K -35.05% $0.00 22.7K Aug 9, 2022 Common Stock 12.3K $9.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 8, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.06 to $228.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.04 to $228.06, inclusive.
F4 This option vested as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of August 8, 2018.
F5 This option vests as to 12.5% of the shares underlying the option award on each six month anniversary following the vesting commencement date of March 21, 2019.